Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: A phase 2 study

Radiotherapy and Oncology

Volumn 66, Issue 2, 2003, Pages 159-165

  Salem, Naji ^a   Simonian Sauve, Michelle ^a   Rosello, Roland ^a   Alzieu, Claude ^a   Gravis, Gwenaelle ^a   Maraninchi, Dominique ^a   Bladou, Franck ^b  

^a INSTITUT PAOLI CALMETTES   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

Author keywords

Acute urinary morbidity; I 125 brachytherapy; Localised prostate carcinoma

Indexed keywords

ANTIANDROGEN; IODINE 125;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DOSIMETRY; DYSURIA; ECHOGRAPHY; ENDOSCOPIC SURGERY; FOLLOW UP; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; ORGAN SIZE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE THERAPY; RATING SCALE; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT PLANNING; URETHRA; URINARY TRACT OBSTRUCTION; URINE CATHETER;

EID: 0037297618     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(03)00004-5     Document Type: Article

References (37)

1. Benoit R.M., Naslund M.J., Cohen J.K. Complications after prostate brachytherapy in the Medicare population. Urology. 55:2000;91-96.
2. Blank K.R., Whittington R., Arjomandy B., Wein A.J., Broderick G., Staley J., Malkowicz S.B. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity. Cancer J Sci Am. 5:1999;370-373.
3. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl. 137:1991;113-118.
4. Blasko J.C., Ragde H., Grimm P.D., Cavanagh W. Prostate brachytherapy: Importance of technique. J Clin Oncol. 14:1996;1965-1967.
5. Blasko J.C., Grimm P., Sylvester J., Badiozamani K.R., Hoak D., Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
6. Brown D., Colonias A., Miller R., Benoit R., Cohen J., Arshoun Y., et al. Urinary morbidity with a modified periferal loading technique of transperineal 125-I prostate implantation. Int J Radiat Oncol Biol Phys. 47:2000;353-360.
7. Crook J., Esche B., Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspective. Urology. 47:1996;387-394.
8. Desai J., Stock R.G., Stone N.N., Iannuzzi C., DeWyngaert J.K. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Invest. 6:1998;135-141.
9. Fleming I.D., Cooper J.S., Henson D.E., et al. American Joint Committee on Cancer: Cancer staging handbook. 5th ed:1998;Lippincott-Raven, Philadelphia.
10. Fowler J.E. Jr. Complications of treatment for localized prostate cancer. J Urol. 160:1998;1386.
11. Gelblum D.Y., Potters L., Ashley R., Waldbaum R., Wang X.H., Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 45:1999;59-67.
12. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 48:2000;119-124.
13. Kleinbaum D.G. New York. New York. 1997;Springer-Verlag, New York.
14. Kleinberg L., Wallner K., Roy J., Zelefsky M., Arterbery V.E., Fuks Z., Harrison L. Treatment-related symptoms during the first year following transperineal 125-I prostate implantation. Int J Radiat Oncol Biol Phys. 28:1994;985-990.
15. Krumholtz J.S., Michalski J.M., Sundaram C.P. Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. J Endourol. 14:2000;371-374.
16. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Macklis R., Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 3:1997;78-87.
17. Lawton C.A., Won M., Pilepich M.V., Asbell S.O., Shipley W.U., Hanks G.E., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 21:1991;935-939.
18. Lee N., Wuu C.S., Brody R., Laguna J.L., Katz A.E., Bagiella E., et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;1457-1460.
19. Middleton R.G., Thompson I.M., Austenfeld M.S., Cooner W.H., Correa R.J., Gibbons R.P., et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 154:1995;2144-2148.
20. Nag S., Beyer D., Friedland J., Grimm P., Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:1999;789-799.
21. Nag S., Bice W., DeWyngaert K., Prestidge B., Stock R., Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 46:2000;221-230.
22. Pollack A., Zagars G.K. External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up? Urology. 51:1998;258-264.
23. Ragde H., Elgamal A.A., Snow P.B., Brandt J., Bartolucci A.A., Nadir B.S., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
24. Ragde H., Leroy J.K., Elgamal A.A., Grado G., Nadir B.S. Modern prostate brachytherapy prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 89:2000;135-141.
25. Schultheiss T.E., Lee W.R., Hunt M.A., Hanlon A.L., Peter R.S., Hanks G.E., Late G.I. and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;3-11.
26. Storey M.R., Landgren R.C., Cottone J.L., Stallings J.W., Logan C.W., Fraiser L.P., et al. Transperineal I-125 implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys. 43:1999;565-570.
27. Stock R.G., Stone N.N., Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 35:1996;267-272.
28. Stock R.G., Stone N.N., Tabert A., Iannuzzi C., DeWyngaert J.K. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
29. Stock R.G., Stone N.N., Dalal M., Lo Y.C. What is the optimal dose for I-125 prostate implants? A dose response analysis of long-term urinary symptoms, biochemical control and post-treatment biopsy. Int J Radiat Oncol Biol Phys. 48:(3):2000;74.
30. Stokes S.H., Real J.D., Adams P.W., Clements J.C., Wuertzer B.S., Kan W. Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 37:1997;337-341.
31. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.
32. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
33. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 37:1997;565-569.
34. Wang H., Wallner K., Sutlief S., Blasko J., Russell K., Ellis W. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer. 90:2000;199-205.
35. Yamada Y., Kim M., Cohen G., Zaider M., Venkatramen E., Wallner K.E., et al. An analysis of late urinary toxicity based upon urethra dose volume histograms after transperineal permanent interstitial iodine 125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:(3):2000;76.
36. Zelefsky M.J., Leibel S.A., Gaudin P.B., Kutcher G.J., Fleshner N.E., Venkatramen E.S., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
37. Zelefsky M.J., Hollister T., Raben A., Matthews S., Wallner K.E. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 47:2000;1261-1266.